Seattle Cancer Care Alliance

Clinical Trials

Questions? Call (800) 804-8824

Lymphoma Non-Transplant Trial Finder

Click on the headings below to view relevant trials for the condition listed.

Indolent Lymphoma: Newly Diagnosed/Untreated (2 trials)

Ofatumumab and Bortezomib for Waldenstrom Macroglobulinemia (FH 7574)
A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Rituximab + Lenalidomide vs Chemotherapy (RELEVANCE-7636)
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma. The "RELEVANCE" Trial (Rituximab Lenalidomide Versus Any Chemotherapy)

Indolent Lymphoma: Relapsed/Refractory (6 trials + 3 pending)

DCDT2980S or DCDS4501A in Combination with MabThera/Rituxan for Relapsed Lymphoma (FH 2649)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination With Rituximab or DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-cell Non Hodgkin's Lymphoma
Ofatumumab vs. Rituximab for Relapsed Follicular Lymphoma (FH 2522)
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab
Bendamustine vs. Bendamustine+RO5072759 (FH 2388)
An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma
PF-05082566 for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia

PCI-32765 (Ibrutinib) for Refractory Follicular Lymphoma (UW12043)
An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
GS-1101 + Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (UW12045)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
GS-1101 + Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (UW12046)
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Aggressive Lymphoma: Newly Diagnosed/Untreated (1 trial pending)

Zevalin for Newly Diagnosed Diffuse Large B-cell Lymphoma (FH 7779)
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Aggressive Lymphoma: Relapsed/Refractory (7 trials, 1 pending)

DCDT2980S or DCDS4501A in Combination with MabThera/Rituxan for Relapsed Lymphoma (FH 2649)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination With Rituximab or DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-cell Non Hodgkin's Lymphoma
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab
TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Two Doses of Fostamatinib for Large B-Cell Lymphoma (UW12019)
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Brentuximab Vedotin for Non-Hodgkin Lymphoma (UW11026)
A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)
PF-05082566 for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia

SGN-CD19A for B-Cell Lymphoma (UW12034)
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Hodgkin Lymphoma: Newly Diagnosed/Untreated (0 trials)

Trials pending. None currently open.

Hodgkin Lymphoma: Newly Diagnosed/Advanced Stage (1 trial pending)

A+AVD vs. ABVD as Frontline Therapy for Hodgkin Lymphoma (UW12044)
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Hodgkin Lymphoma: Relapsed/Refractory (2 trials, 1 pending)

TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Brentuximab Vedotin for Relapsed or Refractory CD30+ Lymphoma (FH 7808)
A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every >= 3 Week Brentuximab Vedotin

Brentuximab Vedotin in Combination with Bendamustine for Hodgkin Lymphoma (UW12035)
A Phase 1/2 Single‐Arm, Open‐Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)

Mantle-Cell Lymphoma: Newly Diagnosed/Untreated (0 trials)

Trials pending. None currently open.

Mantle-Cell Lymphoma: Relapsed/Refractory (2 trials)

Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab
PF-05082566 for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

T-Cell Lymphoma (4 trials, 2 pending)

Brentuximab Vedotin for Relapsed or Refractory CD30+ Lymphoma (FH 7808)
A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every >= 3 Week Brentuximab Vedotin
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (FH 6914)
A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy
Alisertib (MLN8237) for Relapsed/Refractory Peripheral T-Cell Lymphoma (UW12009)
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

SGN-35 + CHP vs. CHOP for T-cell Lymphomas
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
UCHT1 Immunotoxin Therapy for T-cell Diseases (UW12031)
A Phase I/II Study of A-dmDT390-bisFv (UCHT1) Fusion Protein in Patients With Surface CD3+ Malignant T Cell Diseases

Chronic Lymphocytic Leukemia: Untreated or Consolidation (2 trials)

TRU-016 with Rituximab for Previously Untreated Chronic Lymphocytic Leukemia (FH 2631)
A Phase 1b, Single-Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Chronic Lymphocytic Leukemia: Relapsed/Refractory (7 trials)

GS-1101 With Bendamustine and Rituximab for Chronic Lymphocytic Leukemia (FH 2597)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
GS-1101 With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (FH 2612)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
GS 1101 for Previously Treated Chronic Lymphocytic Leukemia (FH 2613)
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia
Lenalidomide w/wo Rituximab for NHL or CLL Patients Previously Treated With Donor Stem Cell Transplant (FH 2467)
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab
Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
PF-05082566 for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
PARP Inhibitor BMN 673 for Advanced Hematological Malignancies (UW 11003)
Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies

Special Populations (1 trial)

Vorinostat and Combination Chemotherapy With Rituximab for HIV-Related Lymphoma (2483)
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma

Clinical Trial Finder beta 2 updated 5/7/2013.